Overview

The Gene Technology Act 2000, enacted by the Commonwealth Parliament, establishes a regulatory framework designed to safeguard the health and safety of the public and the environment from potential risks associated with gene technology. This legislation was introduced to address the need for a cohesive regulatory system to oversee the development and application of genetically modified organisms, ensuring that any associated risks are appropriately identified and managed. The Act empowers the Gene Technology Regulator to assess and licence applications for the release of genetically modified products, such as the proposed commercial release of a genetically modified E. coli chicken vaccine by Zoetis Australia Research and Manufacturing Pty Ltd. This vaccine, intended to confer immunity against E. coli infection and disease in poultry, is currently under evaluation to determine its compliance with the regulatory standards set out in the Act. The policy objective of the Act is to ensure that gene technology is regulated in a manner that protects human health, safety, and the environment, while also fostering innovation and the responsible use of genetic technologies.

Scope and Application

The proposed release of the genetically modified E. coli chicken vaccine, as outlined in licence application DIR 125 by Zoetis Australia Research and Manufacturing Pty Ltd, is subject to the regulatory framework of Australia's gene technology system. This framework is overseen by the Gene Technology Regulator, who is responsible for assessing the application and determining whether to issue a licence. The proposed release of the GM vaccine, which aims to provide immunity to E.coli infection and disease in poultry, is intended to be Australia wide, subject to the approval by other relevant authorities and any requirements imposed by state governments for marketing purposes. The assessment process includes a consultation Risk Assessment and Risk Management Plan (RARMP) that concludes the proposed release would pose negligible risk to human health and safety or the environment. The Regulator is inviting written submissions to inform the decision on the licence, which are due by 31 October 2014. The scope of the legislation applies to the commercial release of the GM vaccine and its oversight, and while the primary jurisdiction is Commonwealth, state government requirements and approvals from other authorities such as the Australian Pesticides and Veterinary Medicines Authority are also integral to the process.

Key Provisions

The primary sections of the Gazette C2014G01512 relate to the assessment and proposed commercial release of a genetically modified (GM) E. coli chicken vaccine by Zoetis Australia Research and Manufacturing Pty Ltd (section 1). This vaccine, Poulvac E. coli®, is genetically modified to provide immunity against E. coli infection and disease in poultry. The Gene Technology Regulator is tasked with evaluating the application (DIR 125) and determining whether to issue a licence for the vaccine’s commercial release. Any release will be subject to additional State government requirements and approvals by other relevant authorities such as the Australian Pesticides and Veterinary Medicines Authority (section 2). The Act imposes several obligations on the entities involved. The primary obligation for Zoetis Australia is to ensure that all necessary assessments, including the Risk Assessment and Risk Management Plan (RARMP), are completed and submitted to the Gene Technology Regulator (section 3). The Regulator is required to assess the RARMP and other related documents to determine the potential risks to human health and the environment. Additionally, the Regulator must consider any written submissions received from the public and other stakeholders before making a decision on whether to issue the licence (section 4). Both Zoetis Australia and the Regulator must adhere to the timelines set out in the Gazette, with submissions due by close of business on 31 October 2014 (section 5). Should any party fail to comply with the provisions of the Act or the conditions of the licence, there may be significant consequences. The Act does not explicitly outline specific offences or penalties for non-compliance in the Gazette. However, breaches of gene technology regulations generally can result in civil or criminal penalties, depending on the severity of the breach. Penalties can include fines and, in more serious cases, imprisonment. The exact penalties would be determined by the relevant courts based on the nature and impact of the breach (section 6). It is important for all parties to adhere to the requirements to avoid such consequences.